Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen

8-K filing — Profound Medical Corp. (PROF)

Filed: 2026-10-14 AccNo: 0001171843-26-006615 Size: 235 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Profound Medical shares are trading higher after the company issued Q3 sales guidance above estimates.

Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth

The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.

Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain

Telix Receives FDA's Fast Track Designation For Its BiPASS Program To Trace Prostate Cancer Prior To Biopsy